Board Change • Jul 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Non-Executive Director Sam Sun was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Jun 24
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to HK$3.88, the stock trades at a trailing P/E ratio of 15x. Average trailing P/E is 13x in the Healthcare industry in Hong Kong. Total loss to shareholders of 81% over the past three years. Recent Insider Transactions • Jun 02
Insider recently sold HK$1.8m worth of stock On the 26th of May, Mang Yee Chu sold around 500k shares on-market at roughly HK$3.60 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth HK$5.7m. Despite this recent sale, insiders have collectively bought HK$6.0m more than they sold in the last 12 months. Upcoming Dividend • May 19
Upcoming dividend of HK$0.13 per share Eligible shareholders must have bought the stock before 26 May 2026. Payment date: 24 June 2026. Payout ratio is a comfortable 49% and this is well supported by cash flows. Trailing yield: 3.5%. Lower than top quartile of Hong Kong dividend payers (6.8%). Lower than average of industry peers (4.6%). Valuation Update With 7 Day Price Move • May 14
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to HK$4.10, the stock trades at a trailing P/E ratio of 15.9x. Average trailing P/E is 15x in the Healthcare industry in Hong Kong. Total loss to shareholders of 46% over the past year. New Risk • May 02
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: HK$5.7m This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. This is currently the only risk that has been identified for the company. Reported Earnings • Apr 29
Full year 2025 earnings released: EPS: CN¥0.22 (vs CN¥0.047 in FY 2024) Full year 2025 results: EPS: CN¥0.22 (up from CN¥0.047 in FY 2024). Revenue: CN¥21.0b (up 17% from FY 2024). Net income: CN¥153.0m (up 410% from FY 2024). Profit margin: 0.7% (up from 0.2% in FY 2024). The increase in margin was driven by higher revenue. Recent Insider Transactions • Apr 26
CEO & Executive Chairman recently bought HK$565k worth of stock On the 22nd of April, Buzhen Zhang bought around 100k shares on-market at roughly HK$5.65 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth HK$1.1m. Buzhen has been a buyer over the last 12 months, purchasing a net total of HK$2.5m worth in shares. Recent Insider Transactions • Mar 31
CEO & Executive Chairman recently bought HK$1.1m worth of stock On the 26th of March, Buzhen Zhang bought around 200k shares on-market at roughly HK$5.31 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Buzhen has been a buyer over the last 12 months, purchasing a net total of HK$1.1m worth in shares. New Risk • Mar 25
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Declared Dividend • Mar 25
Dividend of HK$0.13 announced Shareholders will receive a dividend of HK$0.13. Ex-date: 26th May 2026 Payment date: 24th June 2026 Dividend yield will be 2.4%, which is lower than the industry average of 3.7%. Sustainability & Growth Dividend is covered by both earnings (58% earnings payout ratio) and cash flows (10% cash payout ratio). The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. Earnings per share has grown by 44% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Announcement • Mar 24
YSB Inc. announces Annual dividend, payable on June 24, 2026 YSB Inc. announced Annual dividend of HKD 0.1250 per share payable on June 24, 2026, ex-date on May 26, 2026 and record date on May 27, 2026. Reported Earnings • Mar 24
Full year 2025 earnings released: EPS: CN¥0.22 (vs CN¥0.047 in FY 2024) Full year 2025 results: EPS: CN¥0.22 (up from CN¥0.047 in FY 2024). Revenue: CN¥21.0b (up 17% from FY 2024). Net income: CN¥153.0m (up 410% from FY 2024). Profit margin: 0.7% (up from 0.2% in FY 2024). The increase in margin was driven by higher revenue. Announcement • Mar 23
YSB Inc., Annual General Meeting, May 21, 2026 YSB Inc., Annual General Meeting, May 21, 2026. Valuation Update With 7 Day Price Move • Mar 18
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to HK$4.76, the stock trades at a trailing P/E ratio of 32.8x. Average trailing P/E is 11x in the Healthcare industry in Hong Kong. Total loss to shareholders of 37% over the past year. Announcement • Mar 11
YSB Inc. to Report Fiscal Year 2025 Results on Mar 23, 2026 YSB Inc. announced that they will report fiscal year 2025 results on Mar 23, 2026 Valuation Update With 7 Day Price Move • Mar 04
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to HK$4.33, the stock trades at a trailing P/E ratio of 30.2x. Average trailing P/E is 11x in the Healthcare industry in Hong Kong. Total loss to shareholders of 34% over the past year. Valuation Update With 7 Day Price Move • Jan 14
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to HK$6.50, the stock trades at a trailing P/E ratio of 45.7x. Average trailing P/E is 12x in the Healthcare industry in Hong Kong. Total returns to shareholders of 18% over the past year. Recent Insider Transactions • Nov 07
Key Executive recently bought HK$1.5m worth of stock On the 6th of November, Fei Chen bought around 200k shares on-market at roughly HK$7.69 per share. This transaction amounted to 6.7% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Fei has been a buyer over the last 12 months, purchasing a net total of HK$9.3m worth in shares. Valuation Update With 7 Day Price Move • Oct 28
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to HK$9.26, the stock trades at a trailing P/E ratio of 66.7x. Average forward P/E is 9x in the Healthcare industry in Hong Kong. Total returns to shareholders of 28% over the past year. Reported Earnings • Sep 28
First half 2025 earnings released: EPS: CN¥0.12 (vs CN¥0.034 in 1H 2024) First half 2025 results: EPS: CN¥0.12 (up from CN¥0.034 in 1H 2024). Revenue: CN¥9.84b (up 12% from 1H 2024). Net income: CN¥78.1m (up 258% from 1H 2024). Profit margin: 0.8% (up from 0.2% in 1H 2024). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 7.2% growth forecast for the Healthcare industry in Hong Kong. Recent Insider Transactions • Aug 23
Key Executive recently bought HK$515k worth of stock On the 21st of August, Fei Chen bought around 50k shares on-market at roughly HK$10.30 per share. This transaction amounted to 1.7% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth HK$1.0m. Fei has been a buyer over the last 12 months, purchasing a net total of HK$6.2m worth in shares. Announcement • Aug 09
YSB Inc. to Report First Half, 2025 Results on Aug 20, 2025 YSB Inc. announced that they will report first half, 2025 results on Aug 20, 2025 Announcement • Jul 02
YSB Inc. Appoints Rong Shao Member of the Nomination Committee, with Effect from 27 June 2025 The board of directors of YSB Inc. announce that, in response to the amendments to the Corporate Governance Code as set out in Appendix C1 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, which became effective on 1 July 2025, Ms. Rong Shao has been appointed as member of the nomination committee of the Company (the ‘Nomination Committee’) with effect from 27 June 2025. Following this appointment, the Nomination Committee comprises one executive Director (namely Mr. Buzhen Zhang as the chairperson) and three independent non-executive Directors (namely Ms. Rong Shao, Mr. Sam Hanhui Sun and Mr. Hongqiang Zhao). Recent Insider Transactions • Jun 06
Key Executive recently bought HK$500k worth of stock On the 4th of June, Fei Chen bought around 50k shares on-market at roughly HK$10.00 per share. This transaction amounted to 1.9% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth HK$1.9m. Fei has been a buyer over the last 12 months, purchasing a net total of HK$3.7m worth in shares. Announcement • May 21
YSB Inc Approves the Final Dividend for the Year Ended 31 December 2024 YSB Inc. at its annual general meeting held on 21 May 2025, approved the final dividend of RMB 0.075 per share for the year ended 31 December 2024. Announcement • May 09
YSB Inc. (SEHK:9885) announces an Equity Buyback for HKD 100 million worth of its shares. YSB Inc. (SEHK:9885) announces a share repurchase program. Under the program, the company will repurchase up to HKD 100 million worth of its shares. The actual repurchase price of each share shall not exceed 5% above the average closing market price for the shares over the five trading days immediately preceding each repurchase. The company will finance the repurchase shares from its existing available cash, and any shares repurchased under the share repurchase plan will be canceled in due course. The program is subject to the Shareholders’ approval at its upcoming annual general meeting to be held on May 21, 2025. (The program will expire on October 31, 2025. Reported Earnings • Apr 27
Full year 2024 earnings released: EPS: CN¥0.047 (vs CN¥8.26 loss in FY 2023) Full year 2024 results: EPS: CN¥0.047 (up from CN¥8.26 loss in FY 2023). Revenue: CN¥17.9b (up 5.5% from FY 2023). Net income: CN¥30.0m (up CN¥3.22b from FY 2023). Profit margin: 0.2% (up from net loss in FY 2023). Recent Insider Transactions • Apr 24
Key Executive recently bought HK$1.3m worth of stock On the 22nd of April, Fei Chen bought around 200k shares on-market at roughly HK$6.31 per share. This transaction amounted to 10.0% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Fei's only on-market trade for the last 12 months. Announcement • Mar 18
YSB Inc., Annual General Meeting, May 21, 2025 YSB Inc., Annual General Meeting, May 21, 2025. Reported Earnings • Mar 18
Full year 2024 earnings released: EPS: CN¥0.05 (vs CN¥8.26 loss in FY 2023) Full year 2024 results: EPS: CN¥0.05 (up from CN¥8.26 loss in FY 2023). Revenue: CN¥17.9b (up 5.5% from FY 2023). Net income: CN¥30.0m (up CN¥3.22b from FY 2023). Profit margin: 0.2% (up from net loss in FY 2023). The move to profitability was primarily driven by lower expenses. Announcement • Mar 05
YSB Inc. to Report Fiscal Year 2024 Results on Mar 17, 2025 YSB Inc. announced that they will report fiscal year 2024 results on Mar 17, 2025 New Risk • Nov 28
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (6.6% increase in shares outstanding). Recent Insider Transactions Derivative • Sep 12
Key Executive exercised options to buy HK$6.8m worth of stock. On the 5th of September, Fei Chen exercised options to buy 1m shares at a strike price of around HK$3.11, costing a total of HK$3.1m. Since December 2023, Fei has owned 7.30m shares directly. Company insiders have collectively sold HK$13m more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Aug 28
First half 2024 earnings released: EPS: CN¥0.034 (vs CN¥23.70 loss in 1H 2023) First half 2024 results: EPS: CN¥0.034 (up from CN¥23.70 loss in 1H 2023). Revenue: CN¥8.81b (up 11% from 1H 2023). Net income: CN¥21.8m (up CN¥3.19b from 1H 2023). Profit margin: 0.2% (up from net loss in 1H 2023). Announcement • Aug 15
YSB Inc. to Report First Half, 2024 Results on Aug 26, 2024 YSB Inc. announced that they will report first half, 2024 results on Aug 26, 2024 Reported Earnings • Apr 20
Full year 2023 earnings released: CN¥8.26 loss per share (vs CN¥11.88 loss in FY 2022) Full year 2023 results: CN¥8.26 loss per share. Revenue: CN¥17.0b (up 19% from FY 2022). Net loss: CN¥3.19b (loss widened 114% from FY 2022). Announcement • Mar 12
YSB Inc., Annual General Meeting, May 23, 2024 YSB Inc., Annual General Meeting, May 23, 2024. Reported Earnings • Mar 12
Full year 2023 earnings released: CN¥8.26 loss per share (vs CN¥11.88 loss in FY 2022) Full year 2023 results: CN¥8.26 loss per share. Revenue: CN¥17.0b (up 19% from FY 2022). Net loss: CN¥3.19b (loss widened 114% from FY 2022). Revenue is forecast to grow 34% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Healthcare industry in Hong Kong. Announcement • Feb 28
YSB Inc. to Report Fiscal Year 2023 Results on Mar 11, 2024 YSB Inc. announced that they will report fiscal year 2023 results on Mar 11, 2024 Recent Insider Transactions Derivative • Dec 19
Key Executive exercised options and sold HK$13m worth of stock On the 11th of December, Fei Chen exercised 500k options at a strike price of around HK$3.11 and sold these shares for an average price of HK$28.67 per share. This trade did not impact their existing holding. As of today, Fei currently holds no shares directly. Company insiders have collectively sold HK$16m more than they bought, via options and on-market transactions in the last 12 months. Announcement • Nov 15
YSB Inc. Announces Board Changes YSB Inc. announced that Mr. Frank Lin ("Mr. Lin") has tendered his resignation as a non-executive Director of the Company, effective from the date of this announcement. Reported Earnings • Aug 17
First half 2023 earnings released First half 2023 results: CN¥23.70 loss per share. Net loss: CN¥3.17b (flat on 1H 2022). Announcement • Aug 01
YSB Inc. to Report First Half, 2023 Results on Aug 15, 2023 YSB Inc. announced that they will report first half, 2023 results on Aug 15, 2023 Board Change • Jun 29
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CFO, Executive Director & Joint Company Secretary Fei Chen was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Jun 28
YSB Inc. has completed an IPO in the amount of HKD 316.176 million. YSB Inc. has completed an IPO in the amount of HKD 316.176 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,581,200
Price\Range: HKD 20
Discount Per Security: HKD 0.7
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 9,213,200
Price\Range: HKD 20
Discount Per Security: HKD 0.7
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 5,014,400
Price\Range: HKD 20
Discount Per Security: HKD 0.7
Transaction Features: Regulation S; Rule 144A